Substituted aromatic oligomers
The present invention relates to novel chemical compounds formula (I) (C) n —B-(A) m -B—(C) n (I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five- and six-membered heteroaromatic rings, and for a terminal ring B or C also from bicyclic heteroaromatic fused rings having seven to ten ring members, wherein the bond between at least two of the rings A to C may be replaced by a carbonyl group (—CO—), wherein at least two of the rings A to C are substituted with one or two groups R, and wherein each ring A to C further optionally is substituted with one or two groups R 1 . The compounds are useful in therapy, especially therapy of a mammal suffering from a disease involving misfolded or aggregated forms of proteins.
1. A compound of formula (II)
or a pharmaceutically acceptable salt thereof, wherein
each o is independently 0, 1, or 2;
each p is independently 0, 1, or 2;
each u is independently 0, 1, or 2;
each v is independently 0, 1, 2, or 3,
with the proviso that the sum of o, p, u, and v is greater than 1;
each R 5 , R 6 , and R 7 are independently selected from carboxyalkyl, aminoalkyl, acylaminoalkyl, acyloxyalkyl, hydroxyalkyl, alkylsulphonyl, alkylsulphinyl, alkylaminosulphonyl, alkoxycarbonylalkyl, morpholinoalkyl, carboxyalkenyl, hydroxy, alkoxycarbonyl, pyrrolidinecarbonyl, morpholino, cycloalkylcarbamoyl, cyano, trifluoromethoxy, carbamoyl, hydroxyalkoxyalkyl, carbamoylalkyl, hydroxyalkylaminoalkyl, cyanoalkyl, alkylaminoalkyl, aminoalkylaminoalkyl, carboxyalkylaminoalkyl, piperidinealkyl, and piperazinealkyl;
each R 8 is independently selected from halo, alkyl, trifluoromethyl, carboxy, carboxyalkyl, aminoalkyl, acylaminoalkyl, acyloxyalkyl, hydroxyalkyl, alkylsulphonyl, alkylsulphinyl, alkylaminosulphonyl, alkoxycarbonylalkyl, morpholinoalkyl, carboxyalkenyl, hydroxy, alkoxycarbonyl, pyrrolidinecarbonyl, morpholino, cycloalkylcarbamoyl, cyano, trifluoromethoxy, carbamoyl, hydroxyalkoxyalkyl, carbamoylalkyl, hydroxyalkylaminoalkyl, cyanoalkyl, alkylaminoalkyl, aminoalkylaminoalkyl, carboxyalkylaminoalkyl, piperidinealkyl, and piperazinealkyl; and
any alkyl moiety is C 1-6 -alkyl and any alkenyl moiety is C 2-6 -alkenyl, respectively.
2. A pharmaceutical composition comprising a compound according to claim 1 , and optionally, pharmaceutically acceptable buffers, diluents, excipients and/or carriers.
3. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound according to claim 3 , and optionally, pharmaceutically acceptable buffers, diluents, excipients and/or carriers.
5. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a compound according to claim 5 , and optionally, pharmaceutically acceptable buffers, diluents, excipients and/or carriers.
7. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound according to claim 7 , and optionally, pharmaceutically acceptable buffers, diluents, excipients and/or carriers.